or Try an Advanced Search...

    Camidanlumab Tesirine Stocks List

    Symbol Grade Name % Change
    TGTX C TG Therapeutics, Inc. -1.40
    GMAB D Genmab A/S 7.22
    BNOX F Bionomics Limited 3.28
    View As Page of Charts
    Related Industries: Biotechnology Long-Term Care Facilities
    Related Stock Lists: Cancer Monoclonal Antibodies Antibody Drug Conjugate Biopharmaceutical Cd20 Clinical Medicine Drugs Lymphoma Monoclonal Antibody Treatment Of Cancer Acute Myeloid Leukemia Advanced Cancer Advanced Cancers Alzheimer's Disease Amyloid Amyloidosis Antibodies Antineoplastic Drugs Anxiolytics Biotechnology

    Related ETFs - A few ETFs which own one or more of the above listed Camidanlumab Tesirine stocks.

    Symbol Grade Name Weight
    PBE C PowerShares Dynamic Biotech & Genome 3.41
    FBT D First Trust Amex Biotech Index Fund 3.28
    IBB C iShares Nasdaq Biotechnology Index Fund 1.66
    CNCR D Loncar Cancer Immunotherapy ETF 1.32
    WDNA D WisdomTree BioRevolution Fund 1.2
    View all Camidanlumab Tesirine ETFs...
    Compare ETFs
    Compare FBT to CNCR Compare IBB to WDNA Compare PBE to CNCR

        Camidanlumab Tesirine Stocks Recent News

        Date Stock Title
        May 3 GMAB Genmab A/S (NASDAQ:GMAB) Q1 2024 Earnings Call Transcript
        May 3 TGTX TG Therapeutics: Less Room For Doubt About Briumvi
        May 3 TGTX TG Therapeutics, Inc. (NASDAQ:TGTX) Q1 2024 Earnings Call Transcript
        May 3 TGTX Rainbows and Unicorns: TG Therapeutics, Inc. (NASDAQ:TGTX) Analysts Just Became A Lot More Optimistic
        May 3 TGTX Why TG Therapeutics Stock Was Rocketing Higher This Week
        May 3 TGTX TG Therapeutics, Inc. (TGTX) Q1 2024 Earnings Call Transcript
        May 2 GMAB Genmab A/S (GMAB) Q1 2024 Earnings Call Transcript
        May 2 GMAB Genmab A/S 2024 Q1 - Results - Earnings Call Presentation
        May 2 GMAB Genmab reports Q1 results
        May 2 GMAB Genmab Announces Financial Results for the First Quarter of 2024
        May 2 TGTX TG Therapeutics First Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
        May 2 TGTX TG Therapeutics Inc (TGTX) (Q1 2024) Earnings Call Transcript Highlights: Robust Revenue Growth ...
        May 2 TGTX Q1 2024 TG Therapeutics Inc Earnings Call
        May 1 GMAB Genmab Q1 2024 Earnings Preview
        May 1 GMAB Genmab: A Complicated Tale
        May 1 TGTX TG Therapeutics jumps as Q1 Briumvi sales top guidance
        May 1 TGTX TG Therapeutics Inc (TGTX) Surpasses Revenue Estimates in Q1 2024, Despite Widening Net Loss
        May 1 TGTX TG Therapeutics (TGTX) Reports Q1 Loss, Tops Revenue Estimates
        May 1 TGTX TG Therapeutics GAAP EPS of -$0.07 misses by $0.03, revenue of $63.47M beats by $8.86M
        May 1 GMAB Comstock Inc (LODE) Q1 2024 Earnings Call Transcript Highlights: Strategic Investments and ...
        Related Industries: Biotechnology Long-Term Care Facilities
        Related Stock Lists: Cancer Monoclonal Antibodies Antibody Drug Conjugate Biopharmaceutical Cd20 Clinical Medicine Drugs Lymphoma Monoclonal Antibody Treatment Of Cancer Acute Myeloid Leukemia Advanced Cancer Advanced Cancers Alzheimer's Disease Amyloid Amyloidosis Antibodies Antineoplastic Drugs Anxiolytics Biotechnology
        Camidanlumab Tesirine

        Camidanlumab Tesirine (CAM-T) is a monoclonal antibody therapy that is being developed to treat certain types of cancer. It is designed to target and block a protein called PD-L1, which is found on the surface of some cancer cells. By blocking PD-L1, CAM-T is thought to help the body's immune system recognize and attack cancer cells.

        Browse All Tags